secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2025-01-03T23:59:59+00:00
Accession:  0001213900-25-000844
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies closes $6M private placement; funds operations into 2026
---------------------------------------------------------------------

- Raised $6.05M gross from sale of 1,512,500 units at $4.00/unit; each unit has Series A Convertible Preferred share and a warrant.
- Conversion price of preferred is $4.00; warrant exercise price is $4.40 per share.
- Cash runway expected into 2026; 98% of investment from pre-IPO or IPO investors.
- Data update from OST-HER2 Phase 2b trial in osteosarcoma to be announced during JP Morgan Healthcare Conference week.
- Company entered waiver with ELOC investor Square Gate Capital, including cash payments and issuance of additional shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025000844/0001213900-25-000844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025000844/ea0226635-8k_osthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-000844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer